In December 2024, ProQR expanded its collaboration with the Rett Syndrome Research Trust, securing additional funding for a total of up to $9.2 million to support the advancement of AX-2402, an RNA ...

Nature's Toolbox (NTx), a life sciences company developing next-generation platforms for RNA and protein manufacturing, today announced the founding of its Scientific Advisory Board (SAB) with ...

“In general, we have not recommended boosters because there is no clear evidence that people need it. But there probably is ...

A study from the University of Kentucky Martin-Gatton College of Agriculture, Food and Environment offers fresh insights into ...

SAN FRANCISCO, CA, USA I March 13, 2025 I Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE ...

Inside the human eye, the retina is made up of several types of cells, including the light-sensing photoreceptors that initiate the cascade of events that lead to vision.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

COVID and the 1918 flu pandemic gave us playbooks on how to prepare for the next pandemic. But we aren’t using it.

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

In the Boston area, three months into the new year, the mood in the biotech industry has soured and the outlook has clouded.

The integration of Bayesian statistics into modern analytics has redefined industries, and Alexandre Andorra’s work exemplifies its transformative potential. With expertise spanning sports analytics, ...